PT-141
Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
PT-141 is supplied by Bench Grade Peptides as a lyophilized powder in a sealed, lot-numbered vial, for laboratory research use only — not for human or veterinary use.
Its published Certificate of Analysis (lot 00011/0011, analyzed September 3, 2026) is from AV Analytics, a third-party laboratory, and reports 99.76% purity by HPLC; every published lot is listed on the product's COA page. Vials ship at ambient temperature in protective packaging from Florida (Bench Grade Peptides LLC is registered in Dover, Delaware), with storage notes on the lot's certificate.
Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
The primary literature on this compound includes Diamond et al., J Sex Med (2006). The references below link directly to the published record.
Lots are synthesized in the USA and verified by HPLC; where a lot's Certificate of Analysis is published, it is in the COA library. It is supplied strictly for laboratory research use.
Published research
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsKingsberg SA, et al. Obstet Gynecol. 2019.PubMed →
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderSimon JA, et al. Obstet Gynecol. 2019.PubMed →
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionDiamond LE, et al. Int J Impot Res. 2004.PubMed →
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to ViagraRosen RC, et al. Int J Impot Res. 2004.PubMed →